论文部分内容阅读
目的观察降纤酶治疗急性脑梗死伴短暂性脑缺血发作(TIA)的临床疗效。方法52例脑梗死期间伴TIA发作的患者随机分成2组,治疗组(27例)用降纤酶5u加入0.9%生理盐水250ml静滴,连用7天,首剂加倍。对照组(25例)给予血栓通10ml加入0.9%生理盐水250ml静滴,连用15天。分别观察2组治疗前后血液学改变及临床疗效和TIA控制时间。结果治疗组治疗后纤维蛋白原及血液粘度等明显降低,有显著差异(P<0.05),且较对照组降低明显;在控制TIA发作及临床疗效上亦差异有统计学意义。治疗组不良反应轻微,未发现出血性脑梗死及粘膜活动性出血情况。结论应用降纤酶通过调节纤溶系统,迅速控制TIA发作,从而阻断急性脑梗死的进展,降低致残率,且安全、实用。
Objective To observe the clinical efficacy of defibrase in the treatment of acute cerebral infarction with transient ischemic attack (TIA). Methods Fifty-two patients with TIA during cerebral infarction were randomly divided into two groups. The treatment group (27 cases) was treated with defibrase 5u and 0.9% saline 250ml intravenously for 7 days, the first dose was doubled. Control group (25 cases) given Xueshuantong 10ml added 0.9% saline 250ml intravenous infusion, once every 15 days. Hematological changes, clinical efficacy and TIA control time were observed before and after treatment in two groups. Results After treatment, the fibrinogen and blood viscosity of the treatment group decreased significantly (P <0.05), and significantly decreased compared with the control group. There was also a significant difference in the control of the onset of TIA and clinical efficacy. Adverse reactions in the treatment group were mild, hemorrhagic cerebral infarction and mucosal active bleeding were not found. Conclusion Defibrase can be used to control the onset of TIA rapidly by regulating the fibrinolytic system, thus blocking the progression of acute cerebral infarction and reducing the morbidity, which is safe and practical.